NGM Biopharmaceuticals, Inc.

NGM has designed its discovery programs to capitalize on emerging information garnered from clinical studies and human genetic association experiments, and has focused its research on identifying novel targets that exhibit powerful physiological effects and are implicated in human disease. The Company’s discovery platform integrates sophisticated bioinformatics capabilities, relevant animal disease models and a rapid system to assess the physiological activity of prospective targets in the animal models.

This approach allows a comprehensive data set representing the entire human proteome to be prioritized into select pools of prospective candidates based on disease indication and enriched in secreted, biologically active targets, including soluble protein and peptide metabolites, hormones, growth factors, cytokines and cell surface receptors. To identify targets of potential therapeutic utility, NGM developed a robust gene delivery system by which proteins of interest can be expressed or knocked-down in a tissue specific manner. Using this approach, the functional impact of persistently expressing these putative factors can be evaluated in a wide variety of in vivo models and the biological activity of proteins derived from candidate genes can be assessed in actual disease states.

Drug Discovery Platform Type 2 Diabetes Beta-cell Regeneration Muscle Wasting		Drug Discovery Platform NGM has designed its discovery programs to capitalize on emerging information garnered from clinical studies and human genetic association experiments, and has focused its research on identifying novel targets that exhibit powerful physiological effects and are implicated in human disease. The Company’s discovery platform integrates sophisticated bioinformatics capabilities, relevant animal disease models and a rapid system to assess the physiological activity of prospective targets in the animal models. This approach allows a comprehensive data set representing the entire human proteome to be prioritized into select pools of prospective candidates based on disease indication and enriched in secreted, biologically active targets, including soluble protein and peptide metabolites, hormones, growth factors, cytokines and cell surface receptors. To identify targets of potential therapeutic utility, NGM developed a robust gene delivery system by which proteins of interest can be expressed or knocked-down in a tissue specific manner. Using this approach, the functional impact of persistently expressing these putative factors can be evaluated in a wide variety of in vivo models and the biological activity of proteins derived from candidate genes can be assessed in actual disease states.